vs
Side-by-side financial comparison of Chemours Co (CC) and Zoetis (ZTS). Click either name above to swap in a different company.
Zoetis is the larger business by last-quarter revenue ($2.4B vs $1.3B, roughly 1.8× Chemours Co). Zoetis runs the higher net margin — 25.3% vs -3.5%, a 28.8% gap on every dollar of revenue. On growth, Zoetis posted the faster year-over-year revenue change (3.0% vs -2.1%). Zoetis produced more free cash flow last quarter ($732.0M vs $92.0M). Over the past eight quarters, Zoetis's revenue compounded faster (4.4% CAGR vs -1.2%).
The Chemours Company is an American chemical company that was founded in July 2015 as a spin-off from DuPont. It has its corporate headquarters in Wilmington, Delaware, United States. Chemours is the manufacturer of Teflon, the brand name of polytetrafluoroethylene (PTFE), known for its anti-stick properties. It also produces titanium dioxide and refrigerant gases.
Zoetis Inc. (/zō-EH-tis/) is an American drug company, the world's largest producer of medicine and vaccinations for pets and livestock. The company was a subsidiary of Pfizer, the world's largest drug maker, but with Pfizer's spinoff of its 83% interest in the firm it is now a completely independent company. The company directly markets its products in approximately 45 countries, and sells them in more than 100 countries. Operations outside the United States accounted for 50% of the total re...
CC vs ZTS — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.3B | $2.4B |
| Net Profit | $-47.0M | $603.0M |
| Gross Margin | 11.7% | 70.2% |
| Operating Margin | — | 31.9% |
| Net Margin | -3.5% | 25.3% |
| Revenue YoY | -2.1% | 3.0% |
| Net Profit YoY | -261.5% | 3.8% |
| EPS (diluted) | $-0.32 | $1.37 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.3B | $2.4B | ||
| Q3 25 | $1.5B | $2.4B | ||
| Q2 25 | $1.6B | $2.5B | ||
| Q1 25 | $1.4B | $2.2B | ||
| Q4 24 | $1.4B | $2.3B | ||
| Q3 24 | $1.5B | $2.4B | ||
| Q2 24 | $1.6B | $2.4B | ||
| Q1 24 | $1.4B | $2.2B |
| Q4 25 | $-47.0M | $603.0M | ||
| Q3 25 | $46.0M | $721.0M | ||
| Q2 25 | $-380.0M | $718.0M | ||
| Q1 25 | $-5.0M | $631.0M | ||
| Q4 24 | $-13.0M | $581.0M | ||
| Q3 24 | $-32.0M | $682.0M | ||
| Q2 24 | $60.0M | $624.0M | ||
| Q1 24 | $54.0M | $599.0M |
| Q4 25 | 11.7% | 70.2% | ||
| Q3 25 | 15.6% | 71.5% | ||
| Q2 25 | 17.2% | 73.6% | ||
| Q1 25 | 17.3% | 72.0% | ||
| Q4 24 | 19.4% | 69.5% | ||
| Q3 24 | 19.0% | 70.6% | ||
| Q2 24 | 19.8% | 71.7% | ||
| Q1 24 | 20.9% | 70.6% |
| Q4 25 | — | 31.9% | ||
| Q3 25 | 2.5% | 37.0% | ||
| Q2 25 | -15.4% | 36.7% | ||
| Q1 25 | — | 36.5% | ||
| Q4 24 | -0.1% | 31.6% | ||
| Q3 24 | -2.1% | 36.6% | ||
| Q2 24 | 4.4% | 33.0% | ||
| Q1 24 | 5.1% | 34.1% |
| Q4 25 | -3.5% | 25.3% | ||
| Q3 25 | 3.1% | 30.0% | ||
| Q2 25 | -23.5% | 29.2% | ||
| Q1 25 | -0.4% | 28.4% | ||
| Q4 24 | -1.0% | 25.1% | ||
| Q3 24 | -2.1% | 28.6% | ||
| Q2 24 | 3.9% | 26.4% | ||
| Q1 24 | 4.0% | 27.4% |
| Q4 25 | $-0.32 | $1.37 | ||
| Q3 25 | $0.31 | $1.63 | ||
| Q2 25 | $-2.53 | $1.61 | ||
| Q1 25 | $-0.03 | $1.41 | ||
| Q4 24 | $-0.07 | $1.29 | ||
| Q3 24 | $-0.22 | $1.50 | ||
| Q2 24 | $0.39 | $1.37 | ||
| Q1 24 | $0.36 | $1.31 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $670.0M | — |
| Total DebtLower is stronger | $4.1B | — |
| Stockholders' EquityBook value | $250.0M | $3.3B |
| Total Assets | $7.4B | $15.5B |
| Debt / EquityLower = less leverage | 16.40× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $670.0M | — | ||
| Q3 25 | $613.0M | $2.1B | ||
| Q2 25 | $502.0M | $1.4B | ||
| Q1 25 | $464.0M | $1.7B | ||
| Q4 24 | $713.0M | $2.0B | ||
| Q3 24 | $596.0M | $1.7B | ||
| Q2 24 | $604.0M | $1.6B | ||
| Q1 24 | $746.0M | $2.0B |
| Q4 25 | $4.1B | — | ||
| Q3 25 | $4.1B | — | ||
| Q2 25 | $4.1B | — | ||
| Q1 25 | $4.1B | — | ||
| Q4 24 | $4.1B | — | ||
| Q3 24 | $4.0B | — | ||
| Q2 24 | $4.0B | — | ||
| Q1 24 | $4.0B | — |
| Q4 25 | $250.0M | $3.3B | ||
| Q3 25 | $274.0M | $5.4B | ||
| Q2 25 | $228.0M | $5.0B | ||
| Q1 25 | $566.0M | $4.7B | ||
| Q4 24 | $571.0M | $4.8B | ||
| Q3 24 | $643.0M | $5.2B | ||
| Q2 24 | $714.0M | $5.0B | ||
| Q1 24 | $753.0M | $5.1B |
| Q4 25 | $7.4B | $15.5B | ||
| Q3 25 | $7.5B | $15.2B | ||
| Q2 25 | $7.5B | $14.5B | ||
| Q1 25 | $7.4B | $14.1B | ||
| Q4 24 | $7.5B | $14.2B | ||
| Q3 24 | $7.5B | $14.4B | ||
| Q2 24 | $7.2B | $14.2B | ||
| Q1 24 | $8.0B | $14.3B |
| Q4 25 | 16.40× | — | ||
| Q3 25 | 14.96× | — | ||
| Q2 25 | 17.99× | — | ||
| Q1 25 | 7.18× | — | ||
| Q4 24 | 7.11× | — | ||
| Q3 24 | 6.20× | — | ||
| Q2 24 | 5.53× | — | ||
| Q1 24 | 5.27× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $137.0M | $893.0M |
| Free Cash FlowOCF − Capex | $92.0M | $732.0M |
| FCF MarginFCF / Revenue | 6.9% | 30.7% |
| Capex IntensityCapex / Revenue | 3.4% | 6.7% |
| Cash ConversionOCF / Net Profit | — | 1.48× |
| TTM Free Cash FlowTrailing 4 quarters | $51.0M | $2.3B |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $137.0M | $893.0M | ||
| Q3 25 | $146.0M | $938.0M | ||
| Q2 25 | $93.0M | $486.0M | ||
| Q1 25 | $-112.0M | $587.0M | ||
| Q4 24 | $138.0M | $905.0M | ||
| Q3 24 | $139.0M | $951.0M | ||
| Q2 24 | $-620.0M | $502.0M | ||
| Q1 24 | $-290.0M | $595.0M |
| Q4 25 | $92.0M | $732.0M | ||
| Q3 25 | $105.0M | $805.0M | ||
| Q2 25 | $50.0M | $308.0M | ||
| Q1 25 | $-196.0M | $438.0M | ||
| Q4 24 | $29.0M | $689.0M | ||
| Q3 24 | $63.0M | $784.0M | ||
| Q2 24 | $-693.0M | $370.0M | ||
| Q1 24 | $-392.0M | $455.0M |
| Q4 25 | 6.9% | 30.7% | ||
| Q3 25 | 7.0% | 33.5% | ||
| Q2 25 | 3.1% | 12.5% | ||
| Q1 25 | -14.3% | 19.7% | ||
| Q4 24 | 2.1% | 29.7% | ||
| Q3 24 | 4.2% | 32.8% | ||
| Q2 24 | -44.6% | 15.7% | ||
| Q1 24 | -28.8% | 20.8% |
| Q4 25 | 3.4% | 6.7% | ||
| Q3 25 | 2.7% | 5.5% | ||
| Q2 25 | 2.7% | 7.2% | ||
| Q1 25 | 6.1% | 6.7% | ||
| Q4 24 | 8.0% | 9.3% | ||
| Q3 24 | 5.0% | 7.0% | ||
| Q2 24 | 4.7% | 5.6% | ||
| Q1 24 | 7.5% | 6.4% |
| Q4 25 | — | 1.48× | ||
| Q3 25 | 3.17× | 1.30× | ||
| Q2 25 | — | 0.68× | ||
| Q1 25 | — | 0.93× | ||
| Q4 24 | — | 1.56× | ||
| Q3 24 | — | 1.39× | ||
| Q2 24 | -10.33× | 0.80× | ||
| Q1 24 | -5.37× | 0.99× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CC
| Titanium Technologies | $563.0M | 42% |
| Thermal And Specialized Solutions | $443.0M | 33% |
| Advanced Performance Materials | $312.0M | 23% |
| Other Non-Reportable Segment | $12.0M | 1% |
ZTS
| Other | $1.3B | 56% |
| Livestock | $234.0M | 10% |
| Pain Sedation | $209.0M | 9% |
| Other Pharmaceuticals | $188.0M | 8% |
| Swine | $125.0M | 5% |
| Poultry | $117.0M | 5% |
| Fish | $81.0M | 3% |
| Other Non Pharmaceuticals | $70.0M | 3% |
| Manufactured Product Other | $18.0M | 1% |
| Medicated Feed Additives | $12.0M | 1% |
